Bank of New York Mellon Corp continued to hold its position in shares of Cytosorbents Corp (NASDAQ:CTSO) during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 25,643 shares of the medical research company’s stock at the end of the first quarter. Bank of New York Mellon Corp’s holdings in Cytosorbents Corp were worth $115,000 as of its most recent SEC filing.

Separately, Skylands Capital LLC boosted its position in shares of Cytosorbents Corp by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock valued at $1,425,000 after buying an additional 293,600 shares in the last quarter. Institutional investors own 9.74% of the company’s stock.

Cytosorbents Corp (NASDAQ:CTSO) traded up 2.22% during mid-day trading on Friday, reaching $4.60. 32,971 shares of the company traded hands. The firm’s market capitalization is $129.30 million. Cytosorbents Corp has a 12-month low of $3.30 and a 12-month high of $6.90. The company’s 50 day moving average price is $4.73 and its 200 day moving average price is $4.85.

Cytosorbents Corp (NASDAQ:CTSO) last released its earnings results on Monday, August 7th. The medical research company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. Cytosorbents Corp had a negative return on equity of 141.14% and a negative net margin of 31.30%. The business had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Equities research analysts predict that Cytosorbents Corp will post ($0.27) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at

CTSO has been the topic of several recent analyst reports. Maxim Group set a $10.00 target price on shares of Cytosorbents Corp and gave the stock a “buy” rating in a report on Monday, May 22nd. B. Riley restated a “buy” rating and issued a $11.25 target price on shares of Cytosorbents Corp in a report on Monday, May 15th. Finally, Aegis reiterated a “buy” rating and issued a $9.00 price target on shares of Cytosorbents Corp in a report on Tuesday, May 9th. Six research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $12.71.

In other Cytosorbents Corp news, insider Phillip P. Chan bought 6,300 shares of Cytosorbents Corp stock in a transaction on Monday, June 5th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $25,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders acquired 17,500 shares of company stock worth $70,620. Insiders own 5.60% of the company’s stock.

About Cytosorbents Corp

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Want to see what other hedge funds are holding CTSO? Visit to get the latest 13F filings and insider trades for Cytosorbents Corp (NASDAQ:CTSO).

Institutional Ownership by Quarter for Cytosorbents Corp (NASDAQ:CTSO)

Receive News & Stock Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related stocks with our FREE daily email newsletter.